Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Boosting the vascularization and regenerative capacity of nanofat by short-term ex vivo pretreatment with erythropoietin.

Pruzzo V., Bonomi F., Limido E., Weinzierl A., Harder Y., Laschke MW.

Animal Study on Chronic Inflammation, published in J Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Transl Med (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42443931
DOI
10.1186/s12967-026-08640-x

Abstract (original English)

Background Erythropoietin (EPO) is a glycoprotein hormone that exerts pro-angiogenic and anti-inflammatory effects. The present study investigated whether this beneficial profile of action is suitable for improving the in vivo performance of nanofat, an emulsified fat derivative that is clinically used in plastic and reconstructive surgery. Results Repeated intravital fluorescent microscopic analyses showed that EPO-pretreated nanofat significantly accelerates and enhances the vascularization of the implants, as evidenced by an earlier onset of blood perfusion and an increased functional microvessel density when compared to controls. This was associated with a reduced inflammatory response to the implants, as indicated by lower numbers of adherent leukocytes in venules of the host tissue. Histological and immunohistochemical analyses further revealed an improved implant integration with an increased collagen I deposition and a higher density of nanofat-derived CD31⁺/green fluorescent protein (GFP + ) microvessels, along with a reduced macrophage and neutrophil infiltration. Methods Nanofat was mechanically generated from subcutaneous adipose tissue of GFP + C57BL/6J mice and incubated for 1 h in Hank's Balanced Salt Solution with or without EPO (3 IU/mL). The pretreated nanofat was seeded onto dermal substitutes, which were implanted into dorsal skinfold chambers of GFP⁻ C57BL/

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsErythropoietinNeovascularization, PhysiologicMice, Inbred C57BLRegenerationMicrovesselsGreen Fluorescent ProteinsInflammationAdipose TissueMice

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research